Outcome of Board Meeting
In continuation of our letter dated 23rd October, 2018 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2018, duly approved by the Board of Directors of the Company, at its meeting... Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q2FY19 and H1FY19 financial results will be held on Friday, 2nd November, 2018 at 5.00 P.M. Please find attached herewith the conference call details. Kindly take note of the same. Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited ('Company')
ALKEM LABORATORIES LTDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2018 ,inter alia, to consider and approve Notice is hereby given to the Stock Exchanges under Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 2nd November, 2018, inter alia,... Shareholding for the Period Ended September 30, 2018
Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click here Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Manish NarangDesignation :- Company Secretary and Compliance Officer Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2018.
In terms of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Certificate received from Practising Company Secretary for the half year ended 30th September, 2018. Kindly take the same on record. Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As per the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both, physical and electronic share transfer facility for Alkem Laboratories Limited (hereinafter referred to as 'the Company') are maintained during the period from 1st April, 2018 to 30th September, 2018 (both days inclusive) by the Company's Registrar and Share Transfer Agent,... Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that pursuant to SEBI circular no. SEBI/LAD-NRO/GN/2018/24 dated 8th June, 2018, mandating transfer of securities of a listed company in dematerialized form only,communications were sent to the shareholder(s) requesting them to dematerialize the shares held by them in physical form. Kindly take the same on record. Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 29th September, 2018 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended 30th September, 2018 are communicated to the Stock Exchanges. Alkem to take maximum hit from combination drug ban: Nomura
Alkem Laboratories will take a maximum hit from the government's decision to ban 328 combination drugs, says Nomura.The Ministry of Health and Famil